Heron Therapeutics (HRTX) Tops Q3 EPS by 10c

Heron Therapeutics (NASDAQ: HRTX) reported Q3 EPS of ($0.51), $0.10 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $23.2 million versus the consensus estimate of $25.51 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Bernstein remains bullish on SpaceX but sees challenges in telecom ambitions
• Investing.com’s stocks of the week